The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2022 | Using the innate immune system to treat MDS & the value of novel immunotherapies
In this video, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, shares some insights into how the innate immune system can be used to treat myelodysplastic syndromes (MDS), highlighting the growing role of anti-CD47 agents. Dr Sallman also explains the potential use of NK-cell therapies in high-risk MDS and acute myeloid leukemia (AML), as well as the importance of understanding the immune microenvironment in patients being treated with these novel agents and combinations. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
